Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-D4) – Biotin

Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-D4) – Biotin

Product No.: LT7061

- -
- -
Product No.LT7061
Clone
NP1-D4
Target
SARS-CoV-2 Nucleocapsid (N)
Product Type
Recombinant Monoclonal Antibody
Alternate Names
COV2-NP1-D4, SARS-CoV-2 Nucleocapsid, SARS-CoV-2 Nucleoprotein, Protein N, SARS-CoV N Protein
Isotype
Human IgG1
Applications
ELISA

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
SARS-CoV-2
Virus
Expression Host
HEK-293 Cells
Immunogen
SARS-CoV-2 Nucleocapsid (N) Protein
Product Concentration
0.5 mg/ml
Formulation
This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Shipping
Ships Overnight on Blue Ice
Applications and Recommended Usage?
Quality Tested by Leinco
ELISA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Anti-SARS-CoV-2 Nucleocapsid, clone NP1-D4, specifically targets an epitope on the SARS-CoV-2 nucleocapsid protein. Furthermore, it is reported to bind to the RNA binding domain of the N protein.
Background
Coronavirus disease 2019 (COVID-19) is caused by the Coronaviridae family virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1. SARS-CoV-2 has four structural proteins encoded by its single-stranded, positive-sense RNA genome: the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins2. The N protein is a highly conserved 46 kDa protein that shares 90% homology with SARS-CoV3. The N protein has an N-terminal (NTD) and C-terminal domain (CTD), which bind to RNA and self-oligomerize, respectively4,5, forming a helical nucleocapsid structure within the viral envelope6. Other functions of the N protein included viral transcription, replication, and modulating cell signaling pathways7,8. The N protein is abundantly expressed during infection, and antibodies3,9 and memory T cells10,11 targeting the N protein have been identified in convalescent sera. Therefore, the N protein is a target in some vaccines and diagnostic assays12. The N protein also has therapeutic potential, as it evades RNAi-mediated antiviral responses13.
Antigen Distribution
The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.
NCBI Gene Bank ID
Research Area
COVID-19
.
Infectious Disease
.
Seasonal and Respiratory Infections
.
Viral
.
IVD Raw Material

References & Citations

1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020.
2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020.
3. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020.
4. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020.
5. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006.
6. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005.
7. Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008.
8. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010.
9. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.
10. Grifoni A., Weiskopf D., Ramirez S.I., et al. Cell. 2020.
11. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020.
12. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(4-5):206-211. 2020.
13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 1-4. 2020.
Indirect Elisa Protocol

Certificate of Analysis

- -
- -

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.